GleamWall
中文EN

RGNX REGENXBIO Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1590877 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-4.6%
TTM net income YoY1.5%
TTM EPS YoY7.5%
Revenue 3-yr CAGR15.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-95.7%
Net margin-113.9%
FCF margin-100.6%
EBITDA margin-85.9%

Returns

ROE-113.2%
ROA-35.4%
ROIC (approx.)-150.2%
Asset turnover0.31x

Leverage & solvency

Liabilities / assets68.2%
Debt / equity0.00x
Current ratio4.74x
Interest coverage-4.06x

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-4.7%
Payout ratio—
Capex / revenue1.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$9.16M$108.02M$6.39M$30.34M$29.73M$21.36M$89.01M$21.21M
Cost of revenue———————$6.32M
Gross profit———————$14.90M
R&D expense$61.01M$56.09M$57.34M$59.61M$56.10M$59.50M$53.09M$50.38M
SG&A expense$20.58M$21.62M$21.31M$22.38M$20.25M$19.88M$20.35M$20.05M
Operating income-$35.53M$29.26M-$83.36M-$57.64M-$52.41M-$63.28M$12.13M-$51.37M
Interest expense$7.47M$7.79M$8.71M$12.28M$13.17M$10.99M$8.57M$9.42M
Net income-$40.74M$22.71M-$90.05M-$67.15M-$61.94M-$70.87M$6.08M-$51.19M
EBITDA-$32.02M$33.02M-$79.50M-$53.77M-$48.52M-$59.37M$16.08M-$47.34M
EPS (basic)-0.620.43-1.72—-1.20-1.380.12—
EPS (diluted)-0.620.43-1.72—-1.20-1.380.12—
Weighted avg. shares (diluted)65.26M53.02M52.43M—51.69M51.48M51.43M—
Balance sheet
Cash & equivalents$95.80M$36.49M$15.23M$34.47M$58.80M$79.56M$130.10M$57.53M
Short-term investments$155.18M$69.03M$135.26M$195.60M$215.40M$243.74M$137.76M$177.16M
Receivables$8.54M$106.75M$10.04M$26.38M$25.35M$20.20M$18.19M$20.47M
Current assets$320.89M$236.16M$186.52M$281.28M$331.97M$373.75M$313.24M$278.00M
PP&E, net$95.35M$98.45M$101.87M$104.86M$107.52M$111.02M$114.50M$117.59M
Total assets$466.04M$386.62M$341.89M$453.03M$525.20M$581.03M$490.93M$465.99M
Current liabilities$67.68M$82.62M$71.11M$118.09M$124.57M$119.54M$106.73M$103.19M
Total liabilities$318.00M$314.85M$320.81M$350.30M$363.75M$367.35M$216.73M$206.34M
Shareholders' equity$148.04M$71.77M$21.08M$102.73M$161.45M$213.68M$274.20M$259.65M
Shares outstanding66.12M54.16M51.62M50.89M50.62M50.39M50.12M49.55M
Cash flow statement
Operating cash flow$38.61M-$62.24M-$76.19M-$52.29M-$55.96M-$49.34M$33.63M-$31.62M
Capital expenditure$194,000$760,000$1.24M$508,000$491,000$391,000$1.02M$1.08M
Free cash flow$38.41M-$63.00M-$77.42M-$52.80M-$56.45M-$49.73M$32.60M-$32.70M
Investing cash flow-$86.15M$65.92M$70.59M$37.54M$42.29M-$140.44M$44.74M$40.27M
Financing cash flow$106.85M$17.57M-$13.64M-$9.58M-$7.08M$139.23M-$5.79M-$7.74M
Depreciation & amortization$3.52M$3.76M$3.86M$3.87M$3.89M$3.90M$3.96M$4.02M
Stock-based compensation$8.12M$9.05M$8.62M$8.38M$9.00M$8.65M$8.54M$9.54M

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.